Gosset Ownership
Private
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
NED Biosystems General Information
NED-170 has allowed the first 27 observational patients (mostly heavily pre-treated, late-stage IV) extended survival with some achieving and sustaining no evidence of disease[5]. A Phase 1b/2 clinical trial for NED-170 is being conducted in collaboration with the Institute for Systems Biology[3].
Contact Information
Website
Primary Industry
Biotech
Corporate Office
Cambridge, Massachusetts
United States
United States
Drug Pipeline
NED-170
Phase 1Key Partnerships
Institute for Systems Biology (ISB)
NED Biosystems Funding
No funding data available
To view NED Biosystems's complete valuation and funding history, request access »